STRO Sutro Biopharma Inc.

11.87
0  0%
Previous Close 11.87
Open
Price To Book 2.08
Market Cap 272,124,985
Shares 22,925,441
Volume 0
Short Ratio
Av. Daily Volume 30,224

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initial safety data at EHA June 15, 2019 - generally well-tolerated
STRO-001
Non-Hodgkin lymphoma (NHL)
Phase 1 initial data due YE 2019.
STRO-002
Ovarian and Endometrial Cancer

Latest News

  1. Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
  2. Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
  3. Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
  4. Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
  5. How free-flowing cash is accelerating small companies' cancer drug trials
  6. Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
  7. Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
  8. Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
  9. Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
  10. Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
  11. Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
  12. DAFNA Capital Management Return, AUM and Holdings
  13. Sutro Achieves $10 Million Milestone Payment from Celgene
  14. This year's Bay Area IPO batch remains up 44% despite market turbulence
  15. Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference
  16. Sutro Biopharma Reports Third Quarter 2018 Financial Results
  17. Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer
  18. Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors
  19. Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma
  20. 24 Bay Area companies have gone public so far this year. Here's how they've done.